Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer

BACKGROUND: To clarify the significant clinicopathological and postdosimetric parameters to predict PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer. METHODS: We studied 200 consecutive patients who received LDR-brachytherapy between July 2004...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Nobumichi, Asakawa, Isao, Fujimoto, Kiyohide, Anai, Satoshi, Hirayama, Akihide, Hasegawa, Masatoshi, Konishi, Noboru, Hirao, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487947/
https://www.ncbi.nlm.nih.gov/pubmed/22974428
http://dx.doi.org/10.1186/1471-2490-12-28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487947/
https://www.ncbi.nlm.nih.gov/pubmed/22974428
http://dx.doi.org/10.1186/1471-2490-12-28

Ejemplares similares